Baxter International Inc.

Baxter Healthcare Sa

Fusion Medical Technologies, Inc.

Other

Arya Medical, Inc.

Felix Vega

Cary J Reich

A Edward Osawa

Donald G Wallace

Narinder S Shargill

Russell J Redmond

Claude A Vidal

Woonza M Rhee

Zhen Qian-Wallis

Darrin James Kent

Michael Collinson

David James Prince

Zhen Qian

John P Fezza

Joseph F Rondinone

Edward A Osawa

A device for performing injections in a patient includes a syringe holder with a needle guard, a cannula extending from the syringe holder, a needle slidably disposed over the cannula, and a slider on the syringe holder. The cannula has a blunt tip and a cannula length, and the needle has a sharp tip and a needle length that is shorter than the cannula length. The slider is coupled with the needle and is configured to slide the needle along the cannula from an extended position, in which the sharp tip of the needle is located at or immediately adjacent the blunt tip of the cannula, to a retracted position, in which the sharp tip is housed within the needle guard of the syringe holder.

Combined needle and cannula

Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.

Rapidly acting dry sealant and methods for use and manufacture

Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.

Fragmented polymeric compositions and methods for their use

Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.

Dry hemostatic compositions and methods for their preparation

A percutaneous tissue track closure assembly ( ) includes a semipermeable barrier ( ) mounted to the distal end of a tubular barrier carrier ( ). The barrier is passed down a tissue track ( ) and into a blood vessel ( ) where the barrier is expanded to close off the blood vessel opening ( ). A syringe device is used to drive a hemostatic flowable material ( ) through a delivery tube ( ) and into the tissue track. The semipermeable barrier permits blood to flow therethrough but prevents passage of the hemostatic flowable material therethrough. The hemostatic material includes a material which swells upon contact with blood, and a blood clotting agent. After an appropriate period of time, the barrier is collapsed and the barrier carrier and delivery tube are removed from the tissue track.

Percutaneous tissue track closure assembly and method

Systems and method for sealing vascular penetrations rely on placement of a temporary barrier on the posterior side of the penetration. Penetrations are then sealed by delivering a hemostatic gel to a region over the penetration, where the barrier both inhibits loss of the gel and promotes back flow of blood into the gel. A combination of natural clotting factors in the blood and hemostatic agents in the gel promote rapid and effective sealing of the vascular penetration. Specific systems for performing the method include a barrier carrier for temporary placement of the barrier within the blood vessel and a gel delivery tube which may be positioned within a tissue tract or line of penetration simultaneously with the barrier carrier to deliver the hemostatic gel.

System and method for sealing vascular penetrations with hemostatic gels

A percutaneous tissue track closure assembly ( ) includes a semipermeable barrier( ) mounted to the distal end of a tubular barrier carrier ( ). The barrier is passed down a tissue track ( ) and into a blood vessel ( ) where the barrier is expanded to close off the blood vessel opening ( ). A syringe device is used to drive a hemostatic flowable material ( ) through a delivery tube ( ) and into the tissue track. The semipermeable barrier permits blood to flow therethrough but prevents passage of the hemostatic flowable material therethrough. The hemostatic material includes a material which swells upon contact with blood, and a blood clotting agent. After an appropriate period of time, the barrier is collapsed and the barrier carrier and delivery tube are removed from the tissue track.

Molecular cross-linked gels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such molecular gels may be applied to target sites in a patient's body by extruding the gel through an orifice at the target site. Alternatively, the gels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.

Growing community of inventors

San Francisco, CA, United States of America

Felix Vega